Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PADI3 | Q9ULW8 | 1/20 | 0.44 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2745029 | 0.93 | EPHX2 (0.47) | EPHX2KMT2APADI3PADI4AOC3 | |
| SCHEMBL18688055 | 0.88 | EPHX2 (0.50) | EPHX2KMT2AOPRD1CASP3 | |
| SCHEMBL2744215 | 0.87 | KMT2A (0.52) | EPHX2KMT2AOPRD1CASP3 | |
| SCHEMBL1921443 | 0.83 | KMT2A (0.50) | EPHX2KMT2APADI3PADI4EPHX1 | |
| SCHEMBL2744031 | 0.83 | EPHX2 (0.43) | EPHX2KMT2APADI3PADI4AOC3 | |
| SCHEMBL2744370 | 0.83 | KMT2A (0.48) | EPHX2KMT2AMDM4TP53CASP3 | |
| SCHEMBL30466803 | 0.80 | EPHX2 (0.47) | EPHX2KMT2AMDM4TP53CASP3 | |
| SCHEMBL20530636 | 0.80 | EPHX2 (0.47) | EPHX2KMT2AMDM4TP53CASP3 | |
| SCHEMBL1855344 | 0.80 | EPHX2 (0.53) | EPHX2KMT2AEPHX1 | |
| SCHEMBL6478104 | 0.80 | TSHR (0.50) | PADI3PADI4AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178579-B2 | Histone deacetylase inhibitors; anticancer agents; antiprotozoa agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-15 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| US-7244853-B2 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
| US-20030187027-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-02 | — | — | US | disclosed |
| WO-2002089782-A2 | DIOXANES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187027-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | EPHX2 1183/4885KMT2A 178/4885PADI3 1732/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | EPHX2 1101/4885KMT2A 178/4885PADI3 1541/4885 |
| US-20080269245-A1 | Dioxanes and uses thereof | UTS2R, MAN2B2, AMDHD2 | EPHX2 755/4885KMT2A 152/4885PADI3 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.